Urapidil powder and injection preparation and preparing method
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- GUANGDONG QIFANG MEDICINES CO LTD
- Publication Date
- 2005-06-15
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Description
technical field
[0001] The invention belongs to the technical field of medicine, and relates to a medicine in a special dosage form for cardiovascular and cerebrovascular diseases and a preparation method thereof. Background technique
[0002] Urapidil is a selective α1-receptor blocker with dual peripheral and central hypotensive effects. Peripheral dilation of blood vessels is mainly through blocking post-synaptic α1 receptors, so that the peripheral resistance is significantly reduced and blood vessels are dilated. The central effect is to reduce blood pressure by activating 5-hydroxytryptamine-1A receptors and reducing the sympathetic feedback of the medullary cardiovascular regulation center. This product has the effect of blocking post-synaptic α1 receptors and blocking peripheral α2 receptors, but the former is the main one. The relaxation effect of this product on venous blood vessels is greater than that on arterial blood vessels, and can reduce renal vascular res...